Agoracom Blog

INTERVIEW: After 478% Increase In Q1 Patients, Empower Clinics $CBDT.ca Adds Telemedicine Access To Physicians and E-Commerce $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 5:30 PM on Tuesday, April 14th, 2020

With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for.  Patient visits increased 800% in February. 590% in March and 480% for Q1.  But will Coronavirus social gathering imitations put the clinic network at risk?

No.  In fact, it has had the opposite effect, with the clinics being designated an essential service.  Moreover, Empower had to actually increase operating hours due to demand from existing patients who need their CBD medication more than ever, as well as, new patients who are experiencing anxiety and stress through the COVID-19 pandemic.

BUT THAT WASN’T ENOUGH

The Company has now entered expanded into telemedicine across multiple states for patients who can’t get to a clinic but need a consultation with doctors over the phone to determine the best CBD medications, as well as, 250 new homeopath products for their newly launched immunotherapy initiative …. all which can be fulfilled through the company’s e-commerce platform.

Oh …. and did we mention that psychedelics are on the way?  Empower Clinics has already announced its intention to expand into the field of Psilocybin and psychedelics.  The new telemedicine platform now accelerates this initiative.

Watch this interview with the Company’s CEO, Steven McAuley, who is Six Sigma certified under the quality initiative of legendary GE chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which also explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into real growth.

Grab your favourite beverage and settle in to watch what may be your next great small cap investment

Tags: , , , , ,

Comments are closed.